As exemplified by a recent study of abiraterone, we hypothesized that many oral oncology agents are given in doses far in excess of what is needed, thus enabling the development of value-based dosing strategies incorporating lower doses, less frequent dosing, or even therapeutic substitution. We aimed to identify products for which cost-savings could be > 33%. Methods: We reviewed publicly available documents for all patent-protected oral oncology drugs approved in the US, including official prescribing information, FDA Clinical Pharmacology reviews, and peer-reviewed publications that analyzed the relationship of dose or drug exposure to efficacy. For each drug, we assessed potential costsavings based on publicly available US pricing data, as well as the potential impact on global sales. For those drugs with flat pricing (i.e., where dose reductions would not impact costs), we only considered opportunities to reduce frequency. Results: For 33/53 (62%) oral oncology products, prescribing costs can potentially be reduced by > 33%, with >50% reductions possible for 26 (49%). Strategies include dose reduction (19 drugs, 7 with positive food effect), frequency reduction (13 drugs), and therapeutic substitution (sirolimus for everolimus). Even with current US flat pricing schemes, the potential savings are $91.300þ$33.000 (range $35.700-$186.400) per patient-year for these 33 drugs. Based on recent sales, the potential global savings opportunity is >$12 billion per year, with 75% of the potential savings encompassed by the top six opportunities: ibrutinib ($2.6B), abiraterone ($1.9B), enzalutamide ($1.6B), everolimus ($1.4B), nilotinib ($0.9B), and erlotinib ($0.7B). Conclusions: Development of value-based prescribing strategies has the potential to significantly impact prescribing costs of many oral oncology drugs. Our estimates are likely conservative, given the expanding indications and prolonged treatment courses for many drugs (e.g, ibrutinib and abiraterone). Similar opportunities exist for parenteral monoclonal antibodies with long half-lives. Legal entity responsible for the study: Value in Cancer Care Consortium. 
Department of Radiation Oncology, University Hospitals Leuven, Leuven, Belgium, 3 Belgian Cancer Registry, Brussels, Belgium Background: Known for its accessible health care, Belgium currently counts over 100 hospitals providing oncological care, resulting in shattered care which may negatively influence outcomes. In the context of recent centralization initiatives, this study aimed to evaluate relations between complex surgeries and outcomes for (peri)pancreatic and esophageal cancers at the Belgian population level. Methods: All patients with (peri)pancreatic (ICD)10: C25, C17.0, C24.0-1) or esophageal (C15-C16.0) cancer between 2007 and 2014 were extracted from the Belgian Cancer Registry and linked with surgeries (Sx) from reimbursement data. Concordant with previous reports, three yearly volume categories of Sx per center were defined ((peri)pancreatic: <6, 6-14 and 15 Sx/yr; esophageal: <6, 6-19 and 20 Sx/yr). Relations between surgical volumes and 30-days postoperative mortality as well as 5-year overall survival (OS) were analyzed with multivariable regression models adjusting for case-mix (including age, stage, sex, comorbidities). Results: 16,471 (peri)pancreatic and 12,241 esophageal cancers were retrieved, corresponding to 4,081 (peri)pancreatic and 3,387 esophageal cancer surgeries performed by 96 hospitals in total (in 2014: 68 hospitals for (peri)pancreatic and 54 for esophageal cancer Sx). Surgical volumes were significantly related with 30-days postoperative mortality for (peri)pancreatic and esophageal cancer (p ¼ 0.005 and p < 0.0001 respectively), with 52% and 81% mortality reduction for high vs low volume hospitals, respectively. The volume effect was also seen for OS: for both cancer types, high volume hospitals had a better OS compared to low volume which remained significant after case mix adjustment. For (peri)pancreatic cancer, 1-yr and 5-yr OS for high versus low volume centers was 75% vs 69% and 34% vs 31%, respectively (HR 0.65 [0.55, 0.78 Background: Colorectal cancer predominantly affects adults above 50 years of age, but emerging evidence suggests that, in high-income countries, incidence has been increasing among young adults. Methods: We examined incidence trends for primary, invasive malignancy of the large bowel among all adults (20-99 years) diagnosed during 2001-2014, using joinpoint regression to analyse data from the national cancer registry for England (pop. 55 million). We present the annual percentage change (APC%) in incidence rates by sex, age, deprivation (five categories) and anatomic sub-site.
Results: Annual incidence rates among the youngest adults (20-29 years) increased 3-fold between 2001 and 2014 (APC 7.2% for men, 9.4% for women), with a 2-fold
